Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Camostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.63 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.63 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.63 |
| ▸ | KLK1 | P06870 | 4/20 | 0.63 |
| ▸ | F2 | P00734 | 2/20 | 0.63 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.63 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.63 |
| ▸ | HPN | P05981 | 1/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.63 |
| ▸ | CTSL | P07711 | 1/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.63 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.63 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.63 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camostat SCHEMBL125269 | 0.96 | PRSS1 (0.68) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| SCHEMBL20008640 | 0.96 | PRSS1 (0.68) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL2782237 | 0.95 | PRSS1 (0.67) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL8829828 | 0.94 | PRSS1 (0.66) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL1645380 | 0.93 | PRSS1 (0.64) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL871583 | 0.92 | PRSS1 (0.72) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL23803656 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL1648303 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL1646099 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2TMPRSS2SLC22A2 | |
| Camostat SCHEMBL2326660 | 0.91 | PRSS1 (0.62) | PRSS1KLK1F2TMPRSS2SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253612-A1 | Organic compounds | Novartis AG (CH) | 2010-11-24 | — | — | EP | claimed |
| US-20090203777-A1 | ORGANIC COMPOUNDS | MAAS, JANET CATHERINE (GB) | 2009-08-13 | — | — | US | claimed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | claimed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | claimed |
| WO-2021255218-A1 | A PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-VIRAL PROTONOPHORE AND A SERINE PROTEASE INHIBITOR | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-20120208882-A1 | Organic Compounds | DANAHAY HENRY LUKE (GB) | 2012-08-16 | — | — | US | disclosed |
| EP-2305639-A2 | Organic compounds | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2253612-A1 | Organic compounds | Novartis AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20090203777-A1 | ORGANIC COMPOUNDS | MAAS, JANET CATHERINE (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208882-A1 | Organic Compounds | CFTR, OTC, ASIC1 | ADRA1A 1617/4885OPRD1 626/4885KCNH2 708/4885 |
| US-20090203777-A1 | ORGANIC COMPOUNDS | CFTR, OTC, ASIC1 | ADRA1A 1617/4885OPRD1 626/4885KCNH2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.